Key Takeaways for 2026 Dental Practice Sale Multiples
-
Dental practice sale multiples in 2026 vary widely based on practice size, buyer type, hygiene production, owner dependence, specialty, and payer mix. The spread between low and high ends can be worth millions of dollars.
-
Smaller practices are valued using SDE or collections percentages by individual dentists. Larger practices with $1M+ EBITDA attract DSO and private equity buyers at roughly 5–12× EBITDA, depending on scale and platform status.
-
Key operational drivers that move multiples include owner dependence, hygiene production percentage, payer mix, specialty mix, and regional growth trajectory. Each factor can shift valuation meaningfully within any size tier.
-
A competitive, structured sale process typically adds about 30% in value compared to direct negotiations. McLerran & Associates achieves an 85–90% transaction rate versus an industry norm of 35–40%.
-
Practice owners who understand these factors and obtain a diligence-grade valuation before going to market are better positioned to improve outcomes. Contact McLerran & Associates to see where your practice falls within current 2026 ranges.
How Dental-Practice Sale Multiples Work
A sale multiple is the number applied to a measure of practice earnings to estimate enterprise value. For doctor-to-doctor transactions, that earnings measure is typically Seller’s Discretionary Earnings (SDE), which means net income plus the owner’s compensation and personal add-backs, or a percentage of annual gross collections.
For DSO and private equity transactions, buyers instead use normalized EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization). EBITDA in this context is recalculated after replacing the owner-doctor’s compensation with a market-rate associate salary, so it reflects the practice as a stand-alone business.
The table below summarizes 2026 ranges by buyer type and practice scale, based on triangulated market data.
|
Transaction Path |
Earnings Basis |
Typical 2026 Range |
Primary Buyer |
|---|---|---|---|
|
Doctor-to-doctor (smaller practices) |
SDE or % of collections |
60–85% of collections / 1.5–2.5× SDE |
Individual dentist |
|
DSO / private equity (add-on) |
Normalized EBITDA |
5–8× EBITDA |
DSO tuck-in buyer |
|
DSO / private equity (regional group) |
Normalized EBITDA |
9–11× EBITDA |
Regional DSO or PE platform |
|
DSO / private equity (platform-grade) |
Normalized EBITDA |
10–12×+ EBITDA |
PE-backed DSO or large platform |
These ranges reflect current market conditions, not guarantees. Each practice’s actual multiple depends on the specific factors described below, which is why a diligence-grade valuation usually matters before any conversation with a buyer begins.
Schedule a free, confidential discovery call with McLerran & Associates to see where your practice falls within these ranges.
2026 Multiples by Practice Size and Buyer Type
Practice size strongly influences which buyers engage and how aggressively they bid. Size tends to determine who shows up, while margin quality shapes how those buyers behave once they arrive.
Smaller solo practices with post-doctor-compensation EBITDA under roughly $500,000 are valued primarily by individual dentist buyers using SDE or a percentage of collections. DSOs rarely engage below $250,000 in post-doctor-comp EBITDA, so practices under that level usually face a narrower buyer pool and lower multiples.
As EBITDA grows into the $1 million–$3 million range, the buyer universe expands materially, with multi-location groups attracting DSOs and private equity add-on programs. When EBITDA reaches $3 million–$5 million, practices enter emerging-platform territory where valuations climb further and the higher ranges shown in the earlier table begin to apply. Above $5 million EBITDA, PE-backed DSO platforms close most transactions, often at the upper end of those ranges.
Multi-location regional clusters of 3 or more offices with shared management infrastructure can command a meaningful platform premium. In 2026, regional clusters of 3–10 offices often trade at 9–11× EBITDA, compared to 5–8× for single-location add-ons, which represents roughly a 2×–4× multiple premium.
Operational Drivers That Influence Your Multiple
Within any size tier, operational and financial variables can move the multiple significantly toward the top or bottom of the range. The factors below can be some of the main drivers.
Owner Dependence. Buyers discount practices where the selling doctor produces most of the clinical revenue, because they worry that revenue may not hold after closing. Practices with high owner-doctor production often face a valuation reduction and more contingent deal structures. Practices with associate-led production, where the owner accounts for a smaller share of chair time, usually present lower key-person risk for DSO buyers. Adding producing associates can improve perceived value with institutional buyers.
Hygiene Production Percentage. A strong hygiene department signals a stable, transferable patient base that can remain after the selling dentist exits. Strong hygiene revenue ties closely to a multiple premium because recurring hygiene visits give DSO buyers confidence in forward cash flow. That confidence translates directly into valuation: active hygiene patient retention above 75% tends to lift multiples, while retention below 60% often triggers buyer concerns about long-term revenue durability.
Payer Mix. The balance between insurance plans and fee-for-service revenue can shift the multiple in a meaningful way. Fee-for-service practices with 60% or more of revenue from patients paying directly or through commercial PPOs often command full or above-range EBITDA multiples in 2026, because reimbursement is more predictable and margins per chair are higher. Heavy Medicaid or HMO concentration can compress multiples by roughly 0.5×–1.0× as buyers model reimbursement-rate risk and state-policy exposure.
Specialty Mix. Specialty practices such as oral and maxillofacial surgery, orthodontics, and pediatric dentistry generally command higher multiples than general dentistry when sold to DSO or private equity buyers. These specialties often benefit from stickier referral-driven revenue and higher revenue per patient. General dentistry still earns strong, near-all-time-high valuations in the right size tier. McLerran & Associates evaluates these specialty-by-specialty dynamics rather than treating every practice the same.
Regional Demand and Growth Trajectory. High-growth suburban markets usually attract more buyer competition and higher multiples than rural markets with flat collections and single-doctor production. Three years of consistent revenue and earnings growth also tends to command a premium over flat or declining practices, even when current EBITDA figures look similar.
Doctor-to-Doctor vs. DSO Sale: Practical Comparison
Doctor-to-doctor and DSO transactions differ in valuation method, timeline, post-close expectations, and cash-at-close economics. Understanding both paths helps owners choose a route that fits their goals.
In a doctor-to-doctor transaction, value is typically expressed as a percentage of trailing 12-month gross collections or a multiple of SDE. The timeline from listing to close typically runs 60–120 days, and the seller usually works back only 4–8 weeks before exiting. Cash at close is typically high because the buyer’s SBA loan funds most of the purchase price.
In a DSO or private equity affiliation, value is expressed as a multiple of normalized EBITDA. Typical deal structure runs 60–75% cash at close, 15–30% rollover equity, and 5–15% earnout, with platform deals often tilting toward higher cash percentages. The timeline is longer, usually 3–6 months, and the seller typically commits to a minimum 5-year post-close working agreement. The rollover equity component means the seller effectively becomes an investor in the acquiring organization, which calls for its own due diligence.
For practices in the $1.5 million–$3 million revenue range, both paths can be viable options. McLerran & Associates works both paths in roughly equal measure, about 50/50, which allows for a genuine side-by-side comparison instead of a guess.
Why a Competitive Sale Process Often Adds About 30% Value
A practice owner who negotiates directly with a single buyer, whether an individual dentist or a DSO, usually has no competitive tension working in their favor. The buyer sets the terms of the conversation, and the seller has limited insight into whether the offer reflects the broader market.
McLerran & Associates runs a structured, auction-style bid process that typically lasts 45–60 days and generates around 10 offers from a vetted pool of qualified buyers. That competition tends to move the price. Practices taken to market through a structured multiple-buyer solicitation process receive final sale values averaging about 50% above initial unsolicited offers, according to Q2 2026 dental market data. McLerran’s clients typically see roughly 30% higher valuations than owners achieve when selling on their own.
The firm’s transaction rate reflects the discipline of that process. Roughly 85–90% of McLerran clients transact, compared to an industry norm closer to 35–40% and well above the 15–20% close rate for do-it-yourself sales. About 69% of DSOs expect to increase acquisition activity in 2026, so buyer demand for premier, Class A practices remains strong, and professional representation can help sellers capture that demand.
Schedule a free, confidential discovery call with McLerran & Associates to explore what a competitive process could mean for your practice.
Why Free Valuations Often Break Down in Diligence
A quick, free valuation offered as a lead-generation tool often becomes an anchor. Once a number is in the room, it shapes every negotiation, and a weak number can quietly determine what the owner ultimately receives.
Free valuations also rarely hold up under a buyer’s quality-of-earnings review. Quality-of-earnings reviews in 2026 dental practice sales tend to be more confrontational than in prior years and frequently challenge EBITDA adjustments that were not questioned in 2022–2023. When the valuation analysis cannot defend its add-backs, meaning the discretionary, personal, and non-recurring expenses added back to arrive at true profitability, the deal often gets re-traded downward at a late stage.
McLerran & Associates builds a CPA-led, diligence-grade EBITDA analysis before the practice goes to market. Every add-back is unpacked and documented. The result is a valuation that usually holds when buyers look under the hood and a deal that is less likely to be renegotiated down at the finish line. In one case, a free valuation pegged a practice at $2.5 million, McLerran valued it at $4.5 million, and it sold for $5.25 million after a competitive process.
Readiness Checklist for a Strong 2026 Sale
The operational, financial, and documentation factors below can be some of the most important in determining where a practice lands within its likely multiple range.
-
Associate coverage in place, with the owner producing less than 70–80% of clinical revenue
-
Hygiene department generating above 28–30% of total collections, with recall rates above 75%
-
Three or more years of consistent revenue growth documented in practice management software
-
Payer mix weighted toward fee-for-service or commercial PPO, with Medicaid below 40% of collections
-
Clean, current financials, including profit and loss statements, tax returns, and production reports for the trailing 3 years
-
Lease with 5 or more years remaining, or a renewal option in place
-
Modern equipment and technology, with no significant deferred capital expenditure that a buyer would need to fund post-close
-
Staff tenure and stability, since low turnover signals a practice that can transfer cleanly
-
No significant concentration in a single insurance plan or referral source
-
A clear understanding of your personal “why,” whether that means taking chips off the table, finding a succession partner, or funding growth
Not every box needs to be checked today. McLerran & Associates evaluates more than 500 practices per year and provides candid feedback on where a practice stands and what, if anything, may be worth addressing before going to market. If you are not ready to sell, the firm updates your valuation for free a year later rather than pushing you into a deal.
Next Step: Clarify Your Practice’s Current Value
Dental practice sale multiples in 2026 tend to reward preparation, professional representation, and a competitive process. The spread between a well-run, advisor-led transaction and a do-it-yourself or single-buyer negotiation can reach hundreds of thousands or even millions of dollars.
McLerran & Associates has guided owners through approximately 2,000 successful practice sales and roughly $2 billion in closed transaction volume, working both the doctor-to-doctor and DSO paths in equal measure so clients can see the full picture before deciding.
The first conversation costs nothing and does not commit you to a sale. Schedule a free, confidential discovery call with McLerran & Associates, call (512) 900-7989, email info@dentaltransitions.com, or visit dentaltransitions.com/contact-us to explore what your practice may be worth in today’s market.
Frequently Asked Questions
What is the difference between SDE and EBITDA in a dental practice sale?
SDE, or Seller’s Discretionary Earnings, represents the total financial benefit a single owner-operator receives from the practice. It includes net income plus the owner’s compensation, personal expenses run through the business, and any one-time or non-recurring costs. SDE is the most common earnings basis for smaller, owner-operated practices sold to individual dentist buyers because it reflects what the new owner-operator might actually take home.
EBITDA, or Earnings Before Interest, Taxes, Depreciation, and Amortization, is a different measure used by DSO and private equity buyers. It is calculated after replacing the selling owner’s compensation with a market-rate associate salary. Because EBITDA removes the owner’s personal economics and focuses on the practice’s stand-alone profitability, it usually produces a different number than SDE. DSO buyers then apply a higher multiple to EBITDA, which is one reason larger, more profitable practices often achieve greater total proceeds through the DSO path.
Knowing which metric applies to your practice, and how to calculate it correctly, can be one of the most important early steps in any transition process.
How does owner dependence affect my practice’s sale multiple?
Owner dependence can be one of the most significant factors that compress a dental practice’s sale multiple. When the selling doctor produces the large majority of the practice’s clinical revenue, buyers view that revenue as less durable after the owner exits. The concern is straightforward: if patients follow the selling dentist out the door, the buyer may be paying for cash flow that does not continue.
This risk can reduce the headline multiple and can also shift deal structure toward larger earnout components, which means less cash at close. One of the most effective ways to reduce owner dependence before going to market is to bring on a producing associate and allow that associate to build patient relationships over time. Adding even one producing provider can improve a practice’s value in the eyes of institutional buyers because it signals that revenue can transfer more cleanly after the owner’s exit.
McLerran & Associates evaluates owner dependence as part of every practice valuation and can advise on whether addressing it before going to market is worth the time investment.
Is 2026 a good time to sell a dental practice?
Demand for premier, Class A dental practices remains strong in 2026. DSO acquisition activity is elevated, and a significant majority of DSOs report that their private equity backers expect moderate-to-high increases in acquisition activity this year. Headline EBITDA multiples have held steady for 2 consecutive years after moderating from the peak levels of 2021–2023.
The market has also become more selective. The spread between the best offers and middle-tier offers on any given practice has widened, so stronger practices can still command premium pricing while weaker ones face more scrutiny. Quality-of-earnings reviews are more rigorous than they were 2 or 3 years ago, and deal structures have shifted toward somewhat more deferred consideration compared to the easy-money environment of 2022.
Timing ultimately depends on your specific practice profile and your personal goals. McLerran & Associates provides a candid assessment of how your practice is positioned in the current market and, if the timing does not look favorable, will update your valuation for free a year later.
What does rollover equity mean in a DSO transaction, and should I be concerned about it?
Rollover equity, sometimes called retained equity, refers to the portion of a DSO deal that is paid not in cash at closing but in an ownership stake in the acquiring organization. In many DSO transactions, rollover equity is effectively mandatory and typically represents 15–30% of the total deal value.
Rollover equity can be structured at the joint-venture level, meaning equity in the local operating entity with potential distributions, or at the holding-company level, meaning equity in the broader DSO platform with a higher potential ceiling but no current distributions. Because as much as 40% of a DSO deal can be paid in equity rather than cash, the seller effectively becomes an investor in the acquiring organization, and that investment deserves careful evaluation.
Key questions include whether the DSO is profitable across its existing locations, whether its revenue is still growing, whether the management team is experienced, and whether the private equity firm backing it has a track record of successful exits. McLerran & Associates helps clients underwrite the DSO as an investment, model the equity’s potential value over 3-, 5-, 7-, and 10-year horizons, and compare total after-tax proceeds across deal structures so decisions rest on real economics rather than a headline number.
Why does McLerran & Associates charge for its valuation when other firms offer free valuations?
A free valuation usually serves as a lead-generation tool, meaning a preliminary number produced quickly to start a relationship rather than a defensible analysis built to withstand buyer scrutiny. In today’s environment, where quality-of-earnings reviews are more rigorous than ever, a weak valuation analysis often gets challenged during diligence, and the deal can be re-traded downward. The number that started the conversation then becomes the anchor that shapes what the owner ultimately receives.
McLerran & Associates builds a CPA-led, diligence-grade EBITDA analysis from the ground up by remotely accessing the practice’s management software, pulling the necessary reports, cross-referencing against financials, and unpacking every discretionary, personal, and non-recurring add-back. That work is completed before the practice goes to market, so the valuation is more likely to hold when buyers review it in detail.
The difference in outcome can be substantial, as illustrated by the case described earlier where a practice initially valued at $2.5 million ultimately sold for $5.25 million after McLerran’s diligence-grade analysis and competitive process. The firm’s position is straightforward: it focuses on actually closing practice sales, and the valuation is where that commitment begins.
